Hancock Whitney Corp (NYSE:HWC) Given Average Rating of “Buy” by Analysts

Share on StockTwits

Shares of Hancock Whitney Corp (NYSE:HWC) have been given an average recommendation of “Buy” by the six brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is $52.33.

Several equities research analysts have recently commented on the company. Stephens set a $50.00 price objective on Hancock Whitney and gave the company a “buy” rating in a report on Wednesday, April 17th. Zacks Investment Research cut Hancock Whitney from a “buy” rating to a “sell” rating in a research note on Wednesday, April 3rd.

Shares of NYSE HWC traded down $0.45 during trading hours on Monday, hitting $39.30. The company had a trading volume of 8,618 shares, compared to its average volume of 452,636. Hancock Whitney has a 1-year low of $32.59 and a 1-year high of $53.00. The firm’s 50 day moving average price is $40.94.

Hancock Whitney (NYSE:HWC) last released its quarterly earnings data on Tuesday, April 16th. The company reported $1.00 EPS for the quarter, beating the consensus estimate of $0.98 by $0.02. The company had revenue of $293.58 million during the quarter, compared to analyst estimates of $294.63 million. Hancock Whitney’s revenue was up 6.4% on a year-over-year basis.

The firm also recently declared a quarterly dividend, which was paid on Friday, June 14th. Investors of record on Wednesday, June 5th were paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 2.75%. The ex-dividend date of this dividend was Tuesday, June 4th.

In related news, Director Joan Cahill Teofilo sold 1,150 shares of the stock in a transaction on Friday, June 14th. The stock was sold at an average price of $39.34, for a total value of $45,241.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Hedge funds have recently bought and sold shares of the business. Oregon Public Employees Retirement Fund bought a new position in Hancock Whitney during the 4th quarter worth $34,000. Toronto Dominion Bank bought a new position in shares of Hancock Whitney during the fourth quarter worth about $47,000. FMR LLC bought a new position in shares of Hancock Whitney during the fourth quarter worth about $47,000. Synovus Financial Corp bought a new stake in shares of Hancock Whitney during the fourth quarter valued at approximately $58,000. Finally, JOYN Advisors Inc. bought a new stake in shares of Hancock Whitney during the fourth quarter valued at approximately $88,000.

About Hancock Whitney

Hancock Whitney Corp. is a bank holding company, which engages in the provision of financial services. It also offers trust and investment management services to retirement plans, corporations, and individuals; and brokerage services, annuity products, and life insurance, general insurance agency services, including life and title insurance, consumer financing service.

Featured Article: How Do You Calculate Return on Investment (ROI)?

Analyst Recommendations for Hancock Whitney (NYSE:HWC)

Receive News & Ratings for Hancock Whitney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hancock Whitney and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Novanta  Rating Lowered to Hold at BidaskClub
Novanta Rating Lowered to Hold at BidaskClub
BidaskClub Downgrades Malibu Boats  to Sell
BidaskClub Downgrades Malibu Boats to Sell
Materialise  Stock Rating Upgraded by BidaskClub
Materialise Stock Rating Upgraded by BidaskClub
Rio Tinto  Stock Rating Lowered by Renaissance Capital
Rio Tinto Stock Rating Lowered by Renaissance Capital
Credit Suisse Group Upgrades Ctrip.Com International  to Outperform
Credit Suisse Group Upgrades Ctrip.Com International to Outperform
AtriCure  Raised to “Buy” at Zacks Investment Research
AtriCure Raised to “Buy” at Zacks Investment Research


 
© 2006-2019 Zolmax.